Munaf Alkadimi, M.D.
American Board of Internal Medicine, Board Certified in Medical Oncology, Board Certified in Hematology
Dr. Alkadimi is a member of the American Society of Clinical Oncology, American Society of Hematology, and the Texas Society of Clinical Oncology.
CLINICAL EXPERTISE
Lung cancer, Colorectal cancer, Multiple myeloma, Breast cancer, Genitourinary cancer, Myeloproliferative neoplasms and bone marrow disorders, Leukemia, Lymphoma, Hepatobiliary cancer, Pancreatic cancer, Gastric cancer, Esophageal cancer, Benign Hematology, Clinical research.
EDUCATION
- Medical Degree: Al-Nahrain University, College of Medicine - Baghdad, Iraq
- Residency: University of Chicago - Evanston, Illinois
- Fellowship: University of Texas Health Science Center - San Antonio, Texas
AWARDS
Merit Award, ASCO, 2022. Fellow Award, Texas Society of Clinical Oncology, 2022 & 2023.
Best in Texas Magazine/Doctor edition: 2023 Excellence in Medicine
MEMBERSHIPS:
American Society of Hematology, American Society of Medical Oncology, Texas Society of Clinical Oncology, Texas Medical Association, and the National Arab American Medical Association
HOSPITAL AFFILIATIONS
HCA Medical Center, Memorial Hermann Texas Medical Center, St. Luke’s Episcopal Hospital, Memorial Hermann Northwest Hospital, Cornerstone, Kindred Hospital Houston Medical Center, University General Hospital, Park Plaza Hospital, St. Joseph's Hospital, Methodist Hospital - Texas Medical Center.
PUBLICATIONS
Moore AM, Nooruddin Z, Reveles KR, Datta P, Whitehead JM, Franklin K, Alkadimi M, Williams MH, Williams RA, Smith S, et al. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology. 2023; 30(9):8411-8423. https://doi.org/10.3390/curroncol30090611
Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration. Alkadimi MA, Aldawoodi TA, Lucero KT, Fierro ME, Boyle LD, Mader MJ, Franklin KR, Arora SP, Nooruddin Z. Oncologist. 2024 Jan 22: oyad343. doi: 10.1093/oncolo/oyad343
Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib. Tamarah Aldawoodi, Munaf Alkadimi, Kana Lucero, Lauren Diaz Boyle, Maria Elena Fierro, Michael Mader, Kathleen Franklin, and Zohra Nooruddin. Journal of Clinical Oncology 2023 41:16_suppl, e16195-e16195
Application of the albumin-bilirubin (ALBI) grade as predictive marker of atezolizumab plus bevacizumab (A+B) treatment outcomes for patients with advanced hepatocellular carcinoma (HCC): Real-world retrospective analysis at Veterans Health Administration (VHA).Munaf Alkadimi, Maria Elena Fierro, Lauren Diaz Boyle, Kana Lucero, Kathleen Franklin, Michael Mader, and Zohra Nooruddin. Journal of Clinical Oncology 2023 41:16_suppl, 4107-4107
Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration. Amanda M Moore and others, Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration, The Oncologist, 2023; oyad172, https://doi.org/10.1093/oncolo/oyad172
Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration. Munaf Alkadimi, Kana Lucero, Lauren Diaz Boyle, Maria Elena Fierro, Kathleen Franklin, Zohra Nooruddin, and Michael Mader. Journal of Clinical Oncology 2023 41:16_suppl, 2651-2651
Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration. Moore AM, Nooruddin Z, Reveles KR, Koeller JM, Whitehead JM, Franklin K, Datta P, Alkadimi M, Brannman L, Cotarla I, Frankart AJ, Mulrooney T, Jones X, Frei CR. Oncologist. 2023 Sep 7;28(9):804-811. doi: 10.1093/oncolo/oyad172.
Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system. Lauren Diaz Boyle, Munaf Alkadimi, Maria Elena Fierro, Kana Lucero, Kathleen Franklin, Michael Mader, and Zohra Nooruddin. Journal of Clinical Oncology 2023 41:16_suppl, 4109-4109
The impact of previous local therapy (LT) on overall survival (OS) in patients with advanced hepatocellular carcinoma (aHCC) treated with atezolizumab/bevacizumab (A+B) as first line systemic therapy Maria Elena Fierro, Munaf Alkadimi, Lauren Diaz Boyle, Kana Lucero, Michael Mader, Kathleen Franklin, and Zohra Nooruddin. Journal of Clinical Oncology 2023 41:16_suppl, e16129-e16129
Toxicity profile, palliative care and hospice utilization of geriatric patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the veteran health administration. Kana Lucero, Munaf Alkadimi, Lauren Diaz Boyle, Maria Elena Fierro, Kathleen Franklin, Michael Mader, and Zohra Nooruddin. Journal of Clinical Oncology 2023 41:16_suppl, e24022-e24022
Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration. Munaf Alkadimi, Amanda Moore, Christopher R Frei, Kelly R Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Paromita Datta, Jennifer Whitehead, Kathleen Franklin, Renee Reichelderfer, Madison H. Williams, Ryan A. Williams, Sarah Allison Smith, Xavier Jones, and Zohra Nooruddin. Journal of Clinical Oncology 2022 40:16_suppl, 8554-8554
Does ethnicity matter? A two-statewide population-based analysis of outcomes of primary mediastinal B-cell lymphoma in Hispanics. Munaf Alkadimi, Abhishek Pandya, and Adolfo Enrique Diaz Duque. Journal of Clinical Oncology 2022 40:16_suppl, e19568-e19568
Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities. Paromita Datta, Amanda Moore, Christopher R Frei, Kelly R Reveles, Lance Brannman, Ion Cotarla, Andrew Frankart, Tiernan Mulrooney, Munaf Alkadimi, Jennifer Whitehead, Kathleen Franklin, Renee Reichelderfer, Madison H. Williams, Ryan A. Williams, Sarah Allison Smith, Xavier Jones, and Zohra Nooruddin. Journal of Clinical Oncology 2022 40:16_suppl, 8556-8556
Response rate to chemotherapy after disease progression with anti-PD-1/PD-L1 in metastatic cancer. Munaf Al-Kadhimi, Thomas A. Hensing, Daniel H. Shevrin, Britt Erika Hanson, Nicholas Paul Campbell, and Bruce Brockstein. Journal of Clinical Oncology 2019 37:15_suppl, e14088-e14088
Ambulatory 5FU infusion pumps: Patient perceptions and quality of life. Munaf Al-Kadhimi, Marisa E. Hill, Elita Fine, Matthew Eric Adess, Ari Polish, Lauren Allison Wiebe, Margaret Whalen, Eileen Van Pelt, Teresa Callahan, Cory Gustafson, Kathleen Collins, and Robert de Wilton Marsh. Journal of Clinical Oncology 2019 37:4_suppl, 663-663
Syringoid eccrine carcinoma: A case report and literature review of therapeutic options. Al-Kadhimi M, Al-Dawoodi T, Peguero J, Campos LT. J Case Rep and Images Oncology. 2:57-60,2016.
Autoimmune hemolytic anemia presenting concurrently with thrombotic thrombocytopenic purpura. Al-Kadhimi M, Wah F, Al-Dawoodi T, Peguero J, Campos LT. Case Rep Int. 5:36-39, 2016.
Liquid biopsy in advanced gastric malignancy and molecular targeted therapy; A case report and update pertaining anti Her2-Neu therapy. Al-Kadhimi M, Al-Dawoodi T, Peguero J, Campos LT. J Cancer Sci Clin Oncol. 3(2):1-3,2016. doi: 10.15744/2394-6520.3.202
English, Arabic
